Clinical Trial

Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

Name: Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease — clinical trial record (NCT07514338)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Falcon-OLE

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to investigate if the study medicine, KL1333, is safe, well-tolerated and effective long-term in improving the symptoms of fatigue and impacts on daily living and functional capacity (physical abilities) in people with PMD.

Trial Details

NCT Number	NCT07514338
Lead Sponsor	Pharming Technologies B.V. Collaborators: ICON plc
Conditions	Mitochondrial Diseases
Enrollment	140 participants
Start Date	2026-06-09
Primary Completion	2029-03-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-07